Detoxpc

Other Medications

EU Not submitted to EMA ES Not available 1 Clinical Trials

Description

DetoxPC is marketed as a supportive agent for patients undergoing cancer treatment but lacks clinical evidence to support its use specifically in colorectal cancer. It is not approved by the FDA and should be considered investigational or used with caution outside of research settings.

Mechanism of Action

DetoxPC is a supplement that claims to support detoxification processes and immune function; however, its mechanism of action in the context of colorectal cancer (CRC) has not been scientifically validated.

Side Effects

No specific side effects have been reported for DetoxPC; however Potential interactions with other medications and lack of regulation pose risks.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00019331 Phase 2
Archived
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
United States

Quick Info

CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.